

CONTRACEPTION

AUTHOR INDEX

Volume 30

July - December 1984

- Abdalla, S.A., 413
 Abdel-Aleem, A.M., 391
 Alvarez, F., 443
 Amatayakul, K., 179
 Amortegui, A.J., 135
 Astedt, B., 355
 Atienza, M.F., 99, 215
 Back, D.J., 89, 289
 Balogh, S., 209
 Bélanger, A., 483, 585
 Bergink, E.W., 61
 Bergquist, C., 107
 Blache, D., 279
 Brache, V., 443
 Breckenridge, A.M., 289
 Burkman, R.L., 99, 215
 Carmassi, F., 575
 Casado, M.E., 311
 Chan, S.Y.W., 363
 Chi, I.-C., 209
 Ciavatti, M., 279
 Collins, J.A., 457
 Cordell, G.A., 253
 Coutinho, E., 443
 Croxatto, H.B., 311
 Cullberg, G., 75
 Darwish, H.A., 413
 Davenas, E., 279
 Deleze, M., 29
 Diaz, J., 443
 Diaz, M.M., 443
 Diaz, S., 311, 443
 Diaz-Sanchez, V., 371
 Doong, R.L., 271
 Duffy, T.J., 197
 Elder, M.G., 55
 El-Kabsh, M.Y., 421
 El Mahgoub, S., 125, 443
 El-Nashar, I.M., 391
 El-Sharkawy, M.M., 407
 El Shourbagy, M., 125
 El Tawil, A., 125
 Elwan, S.I., 407, 413, 421
 El Zeniny, A., 125
 Embil, J.A., 457
 Farghaly, A.S., 407, 421
 Faundes, A., 443
 Fianu, A., 23
 Fioretti, P., 575
 Fong, H.H.S., 253
 Ford, S.A., 261
 Fotherby, K., 55
 Fruzzetti, F., 575
 Garza-Flores, J., 371
 Ghaneimah, S.A., 391
 Giasson, M., 585
 Gillett, P.G., 457
 Goldsmith, A., 161
 Goma, A.A., 391
 Gray, R.H., 297
 Grimmer, S.F.M., 289
 Gudmundsson, J.A., 107
 Guillebaud, J., 535
 Gutiérrez, G., 29
 Hagen, D.F., 545
 Hahn, D.W., 39
 Hamawi, A., 55
 Herreros, C., 311
 Honoré, L.H., 555
 Indian Council of Medical
 Research Task Force on
 Female Sterilization, 339
 Indian Council of Medical
 Research Task Force on
 Hormonal Contraception, 561
 Jimenez, J., 523
 Jimenez-Thomas, S., 371
 Johannisson, E., 225
 Jonasson, A., 23
 Jones, A.R., 261
 Juez, G., 311
 Kim, I.C., 253
 Kindahl, H., 23
 King, T.M., 99, 215
 Kirk, M.E., 457
 Kjaeldgaard, A., 169, 355
 Kloosterboer, H.J., 61
 Kuhl, H., 467
 Kurumäki, H., 381, 431
 Labrie, F., 585

CONTRACEPTION

- Lacoste, D., 585
 Lähteenmäki, P., 381
 Lähteenmäki, P.L.A., 143, 381, 431
 Landgren, B.-M., 225
 Larsson, B., 23, 169, 355
 Lawson, J.P., 55
 Lee, R.J., 115
 Lee, S.-Y., 545
 Lehfeldt, H., 331
 Lenker, R.M., 327
 Lindberg, M.C., 81, 599
 Lucas, S., 55
 Lund, L., 61
 Luukkainen, T., 381, 431
 Mao, K., 535
 Marcelle, G.B., 253
 Matlin, S.A., 253
 Mattos, C.E.R., 443
 McGuire, J.L., 39
 Mehrlis, W., 467
 Melder, R.J., 135
 Melis, G.B., 575
 Meyer, M.P., 135
 Mintz, G., 29
 Miranda, P., 311
 Mitra, S.B., 81, 599
 Naqvi, R.H., 81, 599
 Nillius, S.J., 107
 Nummi, S., 61
 Ochoa, M., 523
 Ölund, A., 23
 Orme, M.L'E., 289
 Paoletti, A.M., 575
 Pavez, M., 443
 Peralta, O., 311
 Perlin, I.A., 457
 Pilla, L., 253
 Pirkle, W.H., 253
 Portales, P., 523
 Program for Applied Research
 on Fertility Regulation, 239
 Purba, H.S., 289
 Ray, R., 197
 Renaud, S., 279
 Resch, B., 153
 Richards, G., 457
 Rodríguez, E., 29
 Rosenthale, M.E., 39
 Ruckphaopunt, S., 179
 Rudel, H.W., 371
 Saksena, I.-F., 81
 Salah, M., 391
 Salvatierra, A.M., 311
 Sandow, J., 467
 Sas, M., 153
 Shaaban, M.M., 391, 407, 413, 421
 Singh, B., 135
 Singkamani, R., 179
 Sivin, I., 331, 443
 Smith, G.G., 115
 Soler, M.P., 523
 Stern, J., 443
 Stumpf, P.G., 327
 Tang, L.C.H., 363
 Taubert, H.-D., 457
 Thabet, N., 421
 Tobia, A.J., 39
 Toivonen, J., 381, 431
 Traub, A., 153
 Trayner, I., 55
 Tremblay, Y., 483, 585
 Ugocsai, G., 153
 Uttaravichai, C., 179
 Waller, D.P., 253
 Weber, W., 467
 World Health Organization
 Task Force on Intrauterine
 Devices, 1
 World Health Organization
 Task Force on Oral
 Contraceptives, 505
 Wu, J.T., 271
 Xiao-Nian, M., 89
 Zalányi, S., 225
 Zaneveld, L.J.D., 161
 Zayid, I., 457

CONTRACEPTION

SUBJECT INDEX

Volume 30

July - December 1984

- Abortion,
 - association with pelvic inflammatory disease, 1
 - morbidity risk among young adolescents, 99
- Actinomyces-like organisms, prevalence in cervical smears from IUCD users, 535
- Adhesions,
 - effect of intrauterine quinacrine (monkey), 161
 - effect of intrauterine tetracycline (monkey), 161
- Adolescents, morbidity risk at time of elective abortion, 99
- Adverse pregnancy outcomes, aged gametes and Natural Family Planning, 297
- Aged gametes, adverse pregnancy outcomes and Natural Family Planning, 297
- Albumin level, effect of levonorgestrel, 407
- Alkaline phosphatase activity, effect of levonorgestrel, 407
- Aminopyrine N-demethylase activity, effect of gossypol (rat), 89
- Androst-5-ene-3 α ,17 β -diol level,
 - effect of [D-Tryp⁶]LHRH ethylamide (dog), 483, 585
 - effect of [D-Tryp⁶]LHRH ethylamide + testosterone (dog), 585
- Androstane-3 β ,17 β -diol level,
 - effect of [D-Tryp⁶]LHRH ethylamide (dog), 483, 585
 - effect of [D-Tryp⁶]LHRH ethylamide + testosterone (dog), 585
- Androstane-3 β ,17 β -diol level,
 - effect of [D-Tryp⁶]LHRH ethylamide (dog), 483, 585
 - effect of [D-Tryp⁶]LHRH ethylamide + testosterone (dog), 585
- Androstenedione level,
 - effect of [D-Tryp⁶]LHRH ethylamide (dog), 483, 585
 - effect of [D-Tryp⁶]LHRH ethylamide + testosterone (dog), 585
- Antifertility activity, effect of ORF 13811 (variety of biological test systems), 39
- Antimotility effect on spermatozoa, (\pm)-gossypol, (+)-gossypol, (-)-gossypol and gossypolone, 253
- Antithrombin III level,
 - effect of ethinylestradiol + levonorgestrel, 421
 - effect of levonorgestrel, 421
 - effect of mestranol + norethisterone, 421
- α_1 Antitrypsin level,
 - effect of ethinylestradiol + levonorgestrel, 421
 - effect of levonorgestrel, 421
 - effect of mestranol + norethisterone, 421
- Apolipoprotein A-I level,
 - effect of ethinyloestradiol + desogestrel, 61
 - effect of ethinyloestradiol + levonorgestrel, 61
- Apolipoprotein B level,
 - effect of ethinyloestradiol + desogestrel, 61
 - effect of ethinyloestradiol + levonorgestrel, 61
- Apolipoprotein B/apolipoprotein A-I ratio,
 - effect of ethinyloestradiol + desogestrel, 61
 - effect of ethinyloestradiol + levonorgestrel, 61
- Barrier or natural method users, microbiological and histological findings in the fallopian tubes, 457
- Betadine, effect on metabolic activity of Ureaplasma urealyticum, 135

CONTRACEPTION

- Bile acids level, effect of levonorgestrel, 407
- Bilirubin level, effect of levonorgestrel, 407
- Biological investigation, effect of d-norgestrel (rabbit), 153
- Birth defects, epidemiologic review of Natural Family Planning, 297
- Blastocysts, effect of CI-628 on morphology and 17β -hydroxysteroid dehydrogenase activity (mouse), 271
- Bleeding pattern,
 - effect of levonorgestrel, 391
 - effect of levonorgestrel-releasing IUD, 443
 - effect of nafarelin, 107
 - effect of norethindrone, 239
 - effect of norethisterone enanthate, 225
 - effect of IUC 380Ag, 443
 - use of Copper T200, 311
 - use of progesterone pellets, 311
- Blood coagulation,
 - effect of ethinylestradiol + levonorgestrel, 421
 - effect of levonorgestrel implants, 421
 - effect of mestranol + norethisterone, 421
- Blood pressure,
 - effect of levonorgestrel, 413
 - effect of norethisterone oenanthate, 561
- Body weight,
 - effect of ethinylestradiol (rat), 169
 - effect of ethinyl estradiol + levonorgestrel and multivitamin supplementation, 179
 - effect of gossypol (rat), 89
 - effect of levonorgestrel, 413
 - effect of norethisterone oenanthate, 561
 - effect of d-norgestrel (rat), 169
- Body weight vs method failures, use of norethisterone oenanthate, 561
- Breakthrough bleeding, effect of ethinylestradiol + norethisterone, 371
- Breast-feeding duration, effect of depot-medroxyprogesterone acetate, 523
- Breastfeeding status,
 - use of Copper T200, 311
 - use of progesterone pellets, 311
- Cardiovascular pharmacology,
 - effect of ORF 13811 (variety of biological test systems), 39
 - effect of PGF₂ α (variety of biological test systems), 39
- Carotenoids level, effect of ethinyl estradiol + levonorgestrel and multivitamin supplementation, 179
- Cavity rim cap, use effectiveness, 331
- Cavity-rim cervical cap, survey of use and efficacy, 115
- Ceruloplasmin level,
 - effect of desogestrel, 73
 - effect of levonorgestrel, 407
 - effect of lynestrenol, 73
- Cervical cap,
 - survey of use and efficacy, 115
 - use effectiveness, 331
- Cervical dilatation by laminaria, effect on 15-keto-13,14-dihydro-PGF₂ α level, 23
- Cervical smears, prevalence of actinomyces-like organisms in IUCD users, 535

- Cervix, microbiological findings in women using various contraceptive methods, 457
- Cesarean section, performance of interval insertion of IUDs, 209
- Chlormadinone acetate,
 - effect of basal LH concentrations (rat), 467
 - effect of LH-RH-stimulated LH release (rat), 467
- 6-Chloro-6-deoxyglucose, effect on metabolism of spermatozoa (guinea pig), 261
- (R)- α -Chlorohydrin, effect on metabolism of spermatozoa (guinea pig), 261
- (S)- α -Chlorohydrin, effect on metabolism of spermatozoa (guinea pig), 261
- (R,S)-3-Chlorolactaldehyde, effect on metabolism of spermatozoa (guinea pig), 261
- Chloroquine, effect on pharmacokinetics of ethinylestradiol + levonorgestrel, 289
- CI-628 (1-[2-(p-[α -(p-methoxyphenyl)- β -nitrostyryl]phenoxy)ethyl]-pyrrolidine, monocitrate), effect on morphology and 17 β -hydroxysteroid dehydrogenase activity of blastocysts (mouse), 271
- Clinical outcome, urea + PGF $_2\alpha$ with osmotic dilator or laminaria tent for midtrimester abortion, 215
- Clotting factors II, V, VII through XIII,
 - effect of ethinylestradiol + levonorgestrel, 421
 - effect of levonorgestrel, 421
 - effect of mestranol + norethisterone, 421
- Complementary food in addition to breast milk, effect of hormonal contraceptives in lactating women, 505
- Complications,
 - laparoscopic tubal sterilization in a free-standing clinic, 545
 - relative risk for adolescents undergoing elective abortion, 99
 - tubal sterilization with Filshie Clip, 339
 - urea + PGF $_2\alpha$ with osmotic dilator or laminaria tent for midtrimester abortion, 215
- Conceptrol, effect on metabolic activity of Ureaplasma urealyticum, 135
- Continuation rate,
 - effect of insertion technique in postpartum IUD insertion, 327
 - interval insertion of IUD in women with previous cesarean section, 209
 - use of cavity rim cap, 331
 - use of levonorgestrel-releasing IUD, 443
 - use of norethisterone oenanthate 60 \pm 5-day or 90 \pm 5-day schedule, 561
 - use of Icu 380Ag, 443
- Contraceptive use, association with pelvic inflammatory disease, 1
- Contraceptive vaginal ring, ST-1435-releasing, 381
- Conventional contraceptive use, association with pelvic inflammatory disease, 1
- Copper 7, case report of placental candidiasis with IUCD in situ, 555
- Copper IUCD, prevalence of actinomyces-like organisms in cervical smears, 535
- Copper I, performance in women with previous cesarean section, 209
- Copper T200, fertility regulation in nursing women, 311
- Cord morphology and histology, case reports of placental candidiasis, 555
- Cortisol binding globulin level,
 - effect of desogestrel, 73
 - effect of lynestrenol, 73
- Counselling leaflet on actinomyces-like organisms in cervical smears, 535
- Cycle length, effect of ethinylestradiol + norethisterone, 371

CONTRACEPTION

- Cyproterone acetate,
 - effect on basal LH concentrations (rat), 467
 - effect on LH-RH-stimulated LH release (rat), 467
- Cytochrome P450 level, effect of gossypol (rat), 89
- Dehydroepiandrosterone level,
 - effect of [D-Tryp⁶]LHRH ethylamide (dog), 483, 585
 - effect of [D-Tryp⁶]LHRH ethylamide + testosterone (dog), 585
- Delfen Foam, effect on metabolic activity of Ureaplasma urealyticum, 135
- Depot-medroxyprogesterone acetate,
 - effect on development and health of breast-fed children, 523
 - effect on milk volume and infant growth, 505
- Desogestrel (17 α -ethynyl-18-methyl-11-methylene-4-estrene-17 β -ol),
 - effect on basal LH concentrations (rat), 467
 - effect on LH-RH-stimulated LH release (rat), 467
 - effect on proteins and vaginal cytology, 73
- Development of breast-fed children, effect of depot-medroxyprogesterone acetate in lactating women, 523
- Diabetes mellitus, effect of oral contraceptive use, 197
- Diabetic signs and symptoms, effect of oral contraceptive use, 197
- Dihydrotestosterone level,
 - effect of [D-Tryp⁶]LHRH ethylamide (dog), 483, 585
 - effect of [D-Tryp⁶]LHRH ethylamide + testosterone, 585
- Dilatation of cervix by laminaria tents,
 - clinical evaluations, 215
 - effect on 15-keto-13,14-dihydro-PGF₂ α level, 23
- Dilatation of cervix by osmotic dilators, clinical evaluations, 215
- Discontinuation rate,
 - use of hormonal contraceptives in lactating women, 505
 - use of norethisterone oenanthate 60 \pm 5-day or 90 \pm 5-day schedule, 561
- Dislodgement,
 - use of cavity rim cap, 331
 - use of cervical cap, 115
- Dose of levonorgestrel,
 - effect on kinetic parameters (rat), 599
 - effect on pharmacokinetic parameters (rat), 599
- Dose- and time-dependent alterations of basal and LH-RH-stimulated LH release, treatment with various hormonal contraceptives (rat), 467
- Effectiveness, progesterone implants in nursing women, 311
- Ejaculate volume,
 - effect of [D-Tryp⁶]LHRH ethylamide (dog), 585
 - effect of [D-Tryp⁶]LHRH ethylamide + testosterone (dog), 585
- Emko Foam, effect on metabolic activity of Ureaplasma urealyticum, 135
- Encare oval, effect on metabolic activity of Ureaplasma urealyticum, 135
- Endocrine functions, effect of norethindrone, 239
- Endometrial activity, effect of norethisterone enanthate, 225
- Endometrial changes,
 - effect of intrauterine quinacrine (monkey), 161
 - effect of intrauterine tetracycline (monkey), 161
- Endometrial dating, effect of tubal sterilization, 125
- Endometrium, effect of d-norgestrel (rabbit), 153
- Epidemiologic review, aged gametes, adverse pregnancy outcomes and Natural Family Planning, 297

- Erosion, laceration or pelvic inflammatory disease, use of cavity rim cap, 331
- Estradiol level,
 - effect of desogestrel, 73
 - effect of levonorgestrel, 391, 431
 - effect of lynestrenol, 73
 - effect of nafarelin, 107
 - effect of norethisterone enanthate, 225
 - effect of [D-Tryp⁶]LHRH ethylamide (dog), 585
 - effect of [D-Tryp⁶]LHRH ethylamide + testosterone (dog), 585
- Estrogen deficiency symptoms, effect of nafarelin, 107
- Estrone, effect of CI-628 on production by blastocysts (mouse), 271
- Ethinylestradiol,
 - dissolution rates of different crystal sizes, 371
 - effect on basal LH concentrations (rat), 467
 - effect on fibrinolytic activity in plasma and vessel walls of hind leg (rat), 169
 - effect on LH-RH-stimulated LH release (rat), 467
 - effect on release of tissue-type plasminogen activator, 355
- Ethinyl estradiol + chlormadinone acetate,
 - effect on basal LH concentrations (rat), 467
 - effect on LH-RH-stimulated LH release (rat), 467
- Ethinyl estradiol + cyproterone acetate,
 - effect on basal LH concentrations (rat), 467
 - effect on LH-RH-stimulated LH release (rat), 467
- Ethinyl estradiol + desogestrel,
 - effect on basal LH concentrations (rat), 467
 - effect on Fibrinopeptide A levels, 575
 - effect on LH-RH-stimulated LH release (rat), 467
- Ethinylestradiol + gestoden, effect on Fibrinopeptide A levels, 575
- Ethinylestradiol + levonorgestrel,
 - effect on blood coagulation, 421
 - effect on milk volume and infant growth, 505
 - effect on vitamin metabolism and effects of multivitamin supplementation, 179
- Ethinylestradiol + norethisterone,
 - clinical parameters after administration, 371
 - development of a low-dose monthly injectable contraceptive, 371
 - effect on basal LH concentrations (rat), 467
 - effect on LH-RH-stimulated LH release (rat), 467
- Ethinyl estradiol + norgestrel,
 - effect on basal LH concentrations (rat), 467
 - effect on LH-RH-stimulated LH release (rat), 467
- Ethinylestradiol + d-norgestrel, effect on release of tissue-type plasminogen activator, 355
- Ethinylestradiol level, after subcutaneous injection of ethinylestradiol (rat), 169,
- Ethinylestradiol metabolism, effect of gossypol (rat), 89
- Ethinylestradiol + desogestrel, effect on lipids, apolipoproteins and glycosylated proteins, 61
- Ethinylestradiol + levonorgestrel,
 - effect on lipids, apolipoproteins and glycosylated proteins, 61
 - pharmacokinetics following administration of primaquine and chloroquine, 289

CONTRACEPTION

- Ethinylloestradiol level, after oral administration of ethinylloestradiol + levonorgestrel, 289
- Ethinylestradiol, effect on platelet lipid biosynthesis and aggregation with normal or vitamin E-deficient diet (rat), 279
- Ethinylestradiol + α -tocopherol acetate, effect on platelet lipid biosynthesis and aggregation with normal or vitamin E-deficient diet (rat), 279
- Expulsion,
 - use of levonorgestrel-releasing IUD, 443
 - use of TCu 380Ag, 443
- Expulsion rate,
 - effect of insertion technique in postpartum IUD insertion, 327
 - interval insertion of IUD in women with previous cesarean section, 209
- Failure rate, tubal sterilization with Filshie Clip, 339
- Fallopian tubes, microbiological and histological findings in women using various contraceptive methods, 457
- Fertility, following removal of levonorgestrel implants, 431
- Fertility regulating agents, association with pelvic inflammatory disease, 1
- Fertility regulation in nursing women, progesterone implants, 311
- Fertilizing capacity of spermatozoa, effect of reserpine, 363
- Fibrinogen level,
 - effect of ethinylestradiol + levonorgestrel, 421
 - effect of levonorgestrel, 421
 - effect of mestranol + norethisterone, 421
- Fibrinolytic activity,
 - effect of ethinylestradiol (rat), 169
 - effect of d-norgestrel (rat), 169
- Fibrinopeptide A level,
 - during different phases of menstrual cycle, 575
 - effect of ethinylestradiol + desogestrel, 575
 - effect of ethinylestradiol + gestoden, 575
- Filshie Clip Mark IV, use in tubal sterilization, 339
- First trimester abortion, cervical dilatation by laminaria, 23
- Fitting and insertion, cavity rim cap, 331
- Folate level, effect of ethinyl estradiol + levonorgestrel and multivitamin supplementation, 179
- Follow-up of IUCD users with actinomyces-like organisms in cervical smears, 535
- Follow-up rate, interval insertion of IUD in women with previous cesarean section, 209
- Free-standing clinic, experience with laparoscopic tubal sterilizations, 545
- FSH (follicle stimulating hormone)
- FSH level, effect of levonorgestrel, 391, 431
- Genital tract morphology,
 - effect of intrauterine quinacrine (monkey) 161
 - effect of intrauterine tetracycline (monkey), 161
- Glucose tolerance test,
 - effect of intravaginal ring releasing levonorgestrel, 55
 - effect of oral contraceptive use, 197
- Glutamic oxalacetic transaminase activity, effect of levonorgestrel, 407
- Glutamic pyruvic transaminase activity, effect of levonorgestrel, 407
- γ -Glutamyl transferase activity, effect of levonorgestrel, 407

- Glycosylated proteins level,
 - effect of ethinyloestradiol + desogestrel, 61
 - effect of ethinyloestradiol + levonorgestrel, 61
- GnRH (gonadotropin-releasing hormone)
- GnRH agonist, nafarelin, 107
- Gonadal functions, effect of [D-Tryp⁶]LHRH ethylamide (dog), 483
- Gossypol, effect on hepatic microsomal enzymes (rat), 89
- (-)-Gossypol, spermicidal effect, 253
- (+)-Gossypol, spermicidal effect, 253
- (±)-Gossypol, spermicidal effect, 253
- Gossypolone, spermicidal effect, 253
- Growth of breast-fed children, effect of depot-medroxyprogesterone acetate in lactating women, 523
- Growth of breastfed infants,
 - use of Copper T200, 311
 - use of progesterone pellets, 311
- Haemoglobin, effect of ethinyl estradiol + levonorgestrel and multivitamin supplementation, 179
- Haptoglobin level, effect of levonorgestrel, 407
- hCG (human chorionic gonadotropin)
- hCG/LH level, immediate postabortal use of levonorgestrel implants, 431
- HDL-C (high-density lipoprotein cholesterol)
- HDL-C level,
 - effect of ethinyloestradiol + desogestrel, 61
 - effect of ethinyloestradiol + levonorgestrel, 61
 - effect of levonorgestrel, 55, 413
- HDL-C/TC - HDL-C ratio, effect of levonorgestrel, 413
- Health status of breast-fed children, effect of depot-medroxyprogesterone acetate in lactating women, 523
- Hemoglobin level,
 - effect of levonorgestrel-releasing IUD, 443
 - effect of Icu 380 AG, 443
 - use of norethisterone oenanthate, 561
- Hemopexin level, effect of levonorgestrel, 407
- Hepatic microsomal enzymes, effect of gossypol (rat), 89
- Histological and microbiological findings in fallopian tubes,
 - oral contraceptive pill users, 457
 - use of IUDs, 457
 - use of natural or barrier methods of contraception, 457
- Histology and morphology of cord, case reports of placental candidiasis, 555
- Hormonal changes, levonorgestrel implants, 391
- Hormonal contraceptive, effect on milk volume and infant growth, 505
- 17-Hydroxypregnenolone level,
 - effect of [D-Tryp⁶]LHRH ethylamide (dog), 585
 - effect of [D-Tryp⁶]LHRH ethylamide + testosterone (dog), 585
- 17-Hydroxyprogesterone level,
 - effect of [D-Tryp⁶]LHRH ethylamide (dog), 483, 585
 - effect of [D-Tryp⁶]LHRH ethylamide + testosterone (dog), 585
- 17β-Hydroxysteroid dehydrogenase, effect on activity of blastocysts by CI-628 (mouse), 271
- Immediate postabortal contraception, levonorgestrel implants, 431
- Immobilization of spermatozoa, effect of (±)-gossypol, (+)-gossypol, (-)-gossypol and gossypolone, 253
- Immunoglobulin G, M, and A, effect of levonorgestrel, 407

CONTRACEPTION

- Impaired glucose tolerance, effect of oral contraceptive use, 197
- Implant contraceptive,
 levonorgestrel, 391, 407, 413, 421, 431
 norethindrone, 239
 progesterone, 311
- Implantation, effect of ORF 13811 (variety of biological test systems), 39
- Inert IUCD, prevalence of actinomyces-like organisms in cervical smears, 535
- Infant growth and milk volume,
 effect of ethinyl estradiol + levonorgestrel, 505
 effect of depot-medroxyprogesterone acetate, 505
 effect of dl-norgestrel, 505
- Infant weight, effect of hormonal contraceptives in lactating women, 505
- Inflammation in fallopian tubes, findings in women using various
 contraceptive methods, 457
- Injectable contraceptive,
 ethinylestradiol + norethisterone, 371
 depot-medroxyprogesterone acetate, 505, 523
 norethisterone enanthate, 29, 225, 561
- Injection-abortion interval, urea + PGF₂ α with osmotic dilator or
 laminaria tent for midtrimester abortion, 215
- Insertion characteristics,
 levonorgestrel-releasing IUD, 443
 TCu 380Ag, 443
- Insertion technique, effect on expulsion rate of postpartum IUD insertion, 327
- Insulin or oral agent users, effect of oral contraceptives, 197
- Interval IUD insertion, women with previous cesarean section, 209
- Intestinal absorption, ST-1435 (rat), 143
- Intranasal contraceptive, nafarelin, 107
- Intrauterine contraceptive device (IUCD or IUD),
 copper, 535
 copper 7, 555
 Copper I, 209
 Copper T200, 311
 effect on vitamin metabolism, 179
 inert, 535
 levonorgestrel-releasing, 443
 Lippes Loop, 209
 modified Lippes type, 327
 Multiload, 209
 performance in women with previous cesarean section, 209
 prevalence of actinomyces-like organisms in cervical smears, 535
 TCu 380Ag, 443
- Intrauterine quinacrine pellets and tetracycline tablets, effect on tubal
 occlusion (monkey), 161
- Intravaginal chemical contraceptives, effect on metabolic activity of
 Ureaplasma urealyticum, 135
- Intravaginal ring, releasing levonorgestrel, 55
- IUCD or IUD (intrauterine contraceptive device)
- IUD insertion immediate postpartum, effect of insertion technique on
 expulsion rate, 327
- IUD use,
 association with pelvic inflammatory disease, 1
 microbiological and histological findings in the fallopian tubes, 457

CONTRACEPTION

- 15-Keto-13,14-dihydro-PGF_{2α} level, effect of cervical dilatation by laminaria, 23
- Kinetic parameters, effect of subcutaneous administration of various doses of levonorgestrel (rat), 599
- Koromex II, effect on metabolic activity of Ureaplasma urealyticum, 135
- Laminaria tents for cervical dilatation
 - clinical evaluations, 215
 - effect on 15-keto-13,14-dihydro-PGF_{2α} level, 23
- Lanosterol, effect on platelet aggregation (rat), 279
- Lanosterol + α-tocopherol, effect on platelet aggregation (rat), 279
- Laparoscopic tubal sterilization in a free-standing clinic, 545
- Laparotomy findings, effect of d-norgestrel (rabbit), 153
- LDL-C (low-density lipoprotein cholesterol)
- LDL-C level, effect of levonorgestrel, 55, 413
- Levonorgestrel,
 - effect on basal LH concentrations (rat), 467
 - effect on LH-RH-stimulated LH release (rat), 467
 - intravaginal ring, 55
 - pharmacokinetics (rat), 81, 599
 - radioimmunoassay, 81
 - use in women with systemic lupus erythematosus, 29
- Levonorgestrel implant,
 - effect on blood coagulation, 421
 - effect on liver functions, 407
 - effect on serum lipids, 413
 - hormonal changes, 391
 - immediate postabortal contraception, 431
- Levonorgestrel level,
 - after intravenous administration of levonorgestrel (rat), 81
 - after oral administration of ethinylloestradiol + levonorgestrel, 289
 - effect of subcutaneous administration of various doses (rat), 599
 - use of levonorgestrel implants, 391, 431
- Levonorgestrel-releasing intravaginal ring, effect on lipid levels and glucose tolerance, 55
- Levonorgestrel-releasing IUD, effectiveness, 443
- LH (luteinizing hormone)
- LH level,
 - effect of levonorgestrel, 391, 431
 - effect of norethindrone, 239
- LH release during treatment with various hormonal contraceptives, time- and dose-dependent alterations (rat), 467
- LH-RH (luteinizing hormone releasing hormone)
- LHRH agonist, [D-Tryp⁶,des-Gly-NH₂¹⁰]LHRH ethylamide, 483, 585
- LH-RH-stimulated LH release during treatment with various hormonal contraceptives, time- and dose-dependent alterations (rat), 467
- Lipids,
 - effect of ethinylloestradiol + desogestrel, 61
 - effect of ethinylloestradiol + levonorgestrel, 61
 - effect of intravaginal ring releasing levonorgestrel, 55
 - effect of levonorgestrel implants, 413
- Lippes Loop, performance in women with previous cesarean section, 209
- Lippes type IUD modified for immediate postpartum insertion, effect of insertion technique and expulsion rate, 327
- Liver functions, effect of levonorgestrel implants, 407

CONTRACEPTION

- Liver weight, effect of gossypol (rat), 89
- Luteal function, following tubal sterilization, 125
- Lynestrenol, effect on proteins and vaginal cytology, 73
 - α 2 Macroglobulin level,
 - effect of ethinylestradiol + levonorgestrel, 421
 - effect of levonorgestrel, 421
 - effect of mestranol + norethisterone, 421
- Management of actinomyces-like organisms in cervical smears of IUCD users, 535
- Management of failures, tubal sterilization with Filshie Clip, 339
- Maturation value of vaginal cytology
 - effect of desogestrel, 73
 - effect of lynestrenol, 73
- Menses induction, effect of ORF 13811 (baboon), 39
- Menstrual changes, following tubal sterilization, 125
- Menstrual cycle, Fibrinopeptide A levels during different phases, 575
- Menstrual disturbances, use of norethisterone oenanthate 60 \pm 5-day or 90 \pm 5-day schedule, 561
- Menstrual patterns and pain
 - use of levonorgestrel-releasing IUD, 443
 - use of TCu 380Ag, 443
- Mestranol + norethisterone, effect of blood coagulation, 421
- Metabolic functions, effect of norethindrone, 239
- Metabolism of spermatozoa
 - effect of 6-chloro-6-deoxyglucose (guinea pig), 261
 - effect of (R)- α -chlorohydrin (guinea pig), 261
 - effect of (S)- α -chlorohydrin (guinea pig), 261
 - effect of (R,S)-3-chlorolactaldehyde (guinea pig), 261
- Method failure, use of norethisterone oenanthate, 561
- Microbiological and histological findings in fallopian tubes, oral contraceptive pill users, 457
 - use of IUDs, 457
 - use of natural or barrier methods of contraception, 457
- Microscopic investigation, effect of d-norgestrel (rabbit), 153
- Microsomal protein level, effect of gossypol (rat), 89
- Midtrimester abortion, use of osmotic cervical dilator, 215
- Milk volume and infant growth,
 - effect of ethinyl estradiol + levonorgestrel, 505
 - effect of depot-medroxyprogesterone acetate, 505
 - effect of dl-norgestrel, 505
- Morbidity of breast-fed children, effect of depot-medroxyprogesterone acetate in lactating women, 523
- Morbidity risk, young adolescents undergoing elective abortion, 99
- Morphologic changes of endometrium, effect of norethisterone enanthate, 225
- Morphology, effect on blastocysts by CI-628 (mouse), 271
- Morphology and histology of cord, case reports of placental candidiasis, 555
- Morphometric changes of endometrium, effect of norethisterone enanthate, 225
- Motility of spermatozoa, effect of reserpine, 363
- Multiload, performance in women with previous cesarean section, 209
- Nafarelin (D-Nal(2)⁶-GnRH), inhibition of ovulation by intranasal administration, 107
- Natural Family Planning, epidemiologic review of aged gametes and adverse pregnancy outcomes, 297
- Natural or barrier method users, micorbiological and histological findings in the fallopian tubes, 457

- Nausea, effect of ethinylestradiol + norethisterone, 371
- NeoSampoon tablet, effect on metabolic activity of Ureaplasma urealyticum, 135
- Norethindrone, multicenter clinical trial of subcutaneous implants, 239
- Norethindrone level, use of norethindrone pellet implants, 239
- Norethindrone pellets, norethindrone + cholesterol, 239
- Norethisterone, dissolution rates of different crystal sizes, 371
- Norethisterone enanthate,
 - contraceptive efficacy of 60±5-day and 90±5-day regimens, 561
 - pharmacokinetics, pharmacodynamics and endometrial effects, 225
 - use in women with systemic lupus erythematosus, 29
- Norethisterone level,
 - after intramuscular injection of norethisterone enanthate, 225
 - use of injectable ethinylestradiol + norethisterone system, 371
- d-Norgestrel,
 - biological, microscopic and scanning electron microscopic investigations of effects (rabbit), 153
 - effect on fibrinolytic activity in plasma and vessel walls of hind leg (rat), 169
 - effect on release of tissue-type plasminogen activator, 355
- dl-Norgestrel, effect on milk volume and infant growth, 505
- d-Norgestrel level, after subcutaneous injection of d-norgestrel (rat), 169
- NORPLANT®, contraceptive subdermal implants, 391, 407, 413, 421, 431
- Nursing women, fertility regulation with progesterone implants, 311
- Oral contraceptive,
 - ethinylestradiol + gestoden, 575
 - ethinyl estradiol + levonorgestrel, 179, 421, 505
 - ethinylloestradiol + desogestrel, 61, 575
 - ethinylloestradiol + levonorgestrel, 61, 289
 - levonorgestrel, 29
 - mestranol + norethisterone, 421
 - dl-norgestrel, 505
- Oral contraceptive pill users, microbiological and histological findings in the fallopian tubes, 457
- Oral contraceptive use,
 - association with pelvic inflammatory disease, 1
 - prospective follow-up of women with suspected glucose intolerance, 197
- ORF 13811 (1RS, 4SR, 5RS-4-(5-hydroxy-4,8-dimethyl-7-nonenyl)-4-methyl-3,8-dioxabicyclo[3.2.1]octane-1-acetic acid, a synthetic analog of zoapatanol),
 - antifertility activity (variety of biological test systems), 39
 - pharmacological properties (variety of biological test systems), 39
 - uterotonic activity (guinea pig), 39
- Osmotic cervical dilator, clinical evaluations, 215
- Ovarian reaction, effect of norethisterone enanthate, 225
- Ovarian response, effect of norethindrone, 239
- Ovulation, effect of nafarelin, 107
- Partial thromboplastin time,
 - effect of ethinylestradiol + levonorgestrel, 421
 - effect of levonorgestrel, 421
 - effect of mestranol + norethisterone, 421
- Past history of pelvic inflammatory disease, relative risk of recurrence associated with IUD use, 1

CONTRACEPTION

- Pelvic inflammatory disease,
 - association with abortion, 1
 - association with fertility regulating agents, 1
 - association with sterilization, 1
 - use of levonorgestrel-releasing IUD, 443
 - use of IUCu 380Ag, 443
- PGF_{2α} (prostaglandin F_{2α})
- PGF_{2α} + urea, used with osmotic dilator or laminaria tent for midtrimester abortion, 215
- pH,
 - Betadine, 135
 - chemical intravaginal contraceptives, 135
- Pharmacodynamics, norethisterone enanthate, 225
- Pharmacokinetic parameters, effect of subcutaneous administration of various doses of levonorgestrel (rat), 599
- Pharmacokinetics,
 - effect of primaquine and chloroquine on ethinylestradiol + levonorgestrel, 289
 - ethinylestradiol, 289
 - levonorgestrel, 289
 - levonorgestrel (rat), 81, 599
 - norethisterone enanthate, 225
 - ST-1435, 381
- Pharmacokinetics of levonorgestrel, effect of dose (rat), 599
- Pharmacological properties, effect of ORF 13811 (variety of biological test systems), 39
- Phospholipids level, effect of levonorgestrel, 55
- Placental candidiasis,
 - case report occurring at term, 555
 - case report of copper 7 IUCD in situ, 555
- Plasminogen activator, regulatory effect of contraceptive steroids on release, 355
- Plasminogen level,
 - effect of ethinylestradiol + levonorgestrel, 421
 - effect of levonorgestrel, 421
 - effect of mestranol + norethisterone, 421
- Platelet abnormalities induced by estrogen, effect of vitamin E (rat), 279
- Platelet aggregation, effect of α-tocopherol and ethinylestradiol administration with normal or vitamin E-deficient diet (rat), 279
- Platelet count,
 - effect of ethinylestradiol + levonorgestrel, 421
 - effect of levonorgestrel, 421
 - effect of mestranol + norethisterone, 421
- Platelet lipid biosynthesis, effect of α-tocopherol and ethinylestradiol administration with normal or vitamin E-deficient diet (rat), 279
- Portal plasma, ST-1435 concentration after oral administration (rat), 143
- Postabortal contraception, immediate insertion of levonorgestrel implants, 431
- Postpartum IUD insertion, effect of insertion technique on expulsion rate, 327
- Prealbumin level,
 - effect of desogestrel, 73
 - effect of lynestrenol, 73

- Pregnancy,
 - progesterone pellets in lactating women, 311
 - tubal sterilization with Filshie Clip, 339
 - use of cervical cap, 115
 - use of Copper T200 in lactating women, 311
 - use of intranasal nafarelin, 107
 - use of norethindrone pellet implants, 239
- Pregnancy rate,
 - effect of insertion technique in postpartum IUD insertion, 327
 - interval insertion of IUD in women with previous cesarean section, 209
 - use of cavity rim cap, 331
 - use of levonorgestrel-releasing IUD, 443
 - use of norethisterone oenanthate 60±5-day or 90±5-day schedule, 561
 - use of TCU 380Ag, 443
- Pregnanediol level, effect of norethindrone, 239
- Pregnenolone level,
 - effect of [D-Tryp⁶]LHRH ethylamide (dog), 483, 585
 - effect of [D-Tryp⁶]LHRH ethylamide + testosterone (dog), 585
- Prentif cavity rim cap, use effectiveness, 331
- Prescribed method of use, cavity rim cap, 331
- Primaquine, effect on pharmacokinetics of ethinylestradiol + levonorgestrel, 289
- Progestagen contraceptives, use in women with systemic lupus erythematosus, 29
- Progesterone implants, fertility regulation in nursing women, 311
- Progesterone level,
 - effect of levonorgestrel, 391, 431
 - effect of nafarelin, 107
 - effect of norethisterone enantahte, 225
 - effect of [D-Tryp⁶]LHRH ethylamide (dog), 483, 585
 - effect of [D-Tryp⁶]LHRH ethylamide + testosterone (dog), 585
 - effect of tubal sterilization, 125
 - use of progesterone pellets in lactating women, 311
- Prolactin level, effect of levonorgestrel, 391
- Prostaglandin (PG),
 - 15-keto-13,14-dihydro-PGF_{2α}, 23
 - PGF_{2α}, 39
- Prostaglandin F_{2α} (PGF_{2α}),
 - effect on cardiovascular pharmacology (rat, guinea pig), 39
 - effect on uterine contractility (guinea pig), 39
- Prostate histology,
 - effect of [D-Tryp⁶]LHRH ethylamide (dog), 483, 585
 - effect of [D-Tryp⁶]LHRH ethylamide + testosterone (dog), 585
- Prostate weight,
 - effect of [D-Tryp⁶]LHRH ethylamide (dog), 483, 585
 - effect of [D-Tryp⁶]LHRH ethylamide + testosterone (dog), 585
- Prostatic steroid levels
 - effect of [D-Tryp⁶]LHRH ethylamide (dog), 483, 585
 - effect of [D-Tryp⁶]LHRH ethylamide + testosterone (dog), 585
- Protein level, effect of levonorgestrel, 407
- Proteins,
 - effect of desogestrel, 73
 - effect of lynestrenol, 73

CONTRACEPTION

- Prothrombin time,
 - effect of ethinylestradiol + levonorgestrel, 421
 - effect of levonorgestrel, 421
 - effect of mestranol + norethisterone, 421
- Quinacrine, effect of intrauterine administration on genital tract morphology (monkey), 161
- Radioimmunoassay, levonorgestrel, 81
- Randomized study, TCu 380Ag and levonorgestrel-releasing IUD, 443
- Relative risk,
 - complication for adolescents undergoing elective abortion, 99
 - impaired glucose tolerance and diabetes mellitus with oral contraceptive use, 197
 - pelvic inflammatory disease associated with abortion as outcome of last pregnancy, 1
 - pelvic inflammatory disease associated with contraceptive use, 1
 - recurrent pelvic inflammatory disease associated with current IUD use, 1
- Removal of IUCD, influence on colonization of cervix by actinomyces-like organisms, 535
- Removal rate,
 - effect of insertion technique in postpartum IUD insertion, 327
 - interval insertion of IUD in women with previous cesarean section, 209
- Reserpine (methyl reserpate, 3,4,5-trimethoxybenzoic acid ester),
 - effect of fertilizing capacity of spermatozoa, 363
 - effect of motility of spermatozoa, 363
- Return of fertility, following removal of levonorgestrel implants, 431
- Reversible inhibition of gonadal functions, [D-Tryp⁶]LHRH ethylamide (dog), 483
- Route of sterilization, influence on prognosis, 339
- Scanning electron microscopic investigation, effect of d-norgestrel (rabbit), 153
- Selective inhibition of spermatogenesis,
 - effect of [D-Tryp⁶]LHRH ethylamide (dog), 585
 - effect of [D-Tryp⁶]LHRH ethylamide + testosterone (dog), 585
- Sex ratio, epidemiologic review of Natural Family Planning, 297
- SHBG (sex hormone binding globulin)
- SHBG level,
 - effect of desogestrel, 73
 - effect of lynestrenol, 73
- Side effects,
 - norethindrone pellet implants, 239
 - use of cavity rim cap, 331
 - use of intranasal nafarelin, 107
 - use of norethisterone oenanthate, 561
- Sperm count,
 - effect of [D-Tryp⁶]LHRH ethylamide (dog), 483, 585
 - effect of [D-Tryp⁶]LHRH ethylamide + testosterone (dog), 585
- Spermatogenesis,
 - effect of [D-Tryp⁶]LHRH ethylamide (dog), 585
 - effect of [D-Tryp⁶]LHRH ethylamide + testosterone (dog), 585
- Spermatozoal fertilizing capacity, effect of reserpine, 363
- Spermatozoal metabolism, effect of (S)- α -chlorohydrin and 6-chloro-6-deoxyglucose (guinea pig), 261
- Spermicidal effect, (\pm)-gossypol, (+)-gossypol, (-)-gossypol and gossypolone, 253

CONTRACEPTION

- Spontaneous abortion, epidemiologic review of Natural Family Planning, 297
- SI-1435 (16-methylene-17 α -acetoxy-19-nor-4-pregnene-3,20-dione),
 - intestinal absorption (rat), 143
 - pharmacokinetic observations, 381
- SI-1435 level,
 - after insertion of contraceptive vaginal ring containing SI-1435, 381
 - after insertion of subcutaneous capsules containing SI-1435, 381
 - after oral administration of SI-1435 (rat), 143
- Sterilization,
 - association with pelvic inflammatory disease, 1
 - experience in a free-standing clinic, 545
 - laparoscopic tubal rings, 125
 - Pomeroy's technique, 125
 - use of Filshie Clip Mark IV, 339
- Subdermal capsules, SI-1435, 381
- Survival probability, use of cervical cap, 115
- Suspected glucose intolerance, effect of oral contraceptive use, 197
- Systemic lupus erythematosus, use of progestagen contraceptives, 29
- Systemic venous plasma, SI-1435 concentration after oral administration (rat), 143
- TC (total cholesterol)
- TC level,
 - effect of ethinylloestradiol + desogestrel, 61
 - effect of ethinylloestradiol + levonorgestrel, 61
 - effect of levonorgestrel, 55, 413
- TC/HDL-C ratio, effect of levonorgestrel, 413
- TCu 380Ag, effectiveness, 443
- Termination rate,
 - use of cavity rim cap, 331
 - use of levonorgestrel-releasing IUD, 443
 - use of TCu 380Ag, 443,
- Testicular steroid levels,
 - effect of [D-Tryp⁶]LHRH ethylamide (dog), 483, 585
 - effect of [D-Tryp⁶]LHRH ethylamide + testosterone (dog), 585
- Testis histology,
 - effect of [D-Tryp⁶]LHRH ethylamide (dog), 483, 585
 - effect of [D-Tryp⁶]LHRH ethylamide + testosterone (dog), 585
- Testis weight,
 - effect of [D-Tryp⁶]LHRH ethylamide (dog), 483, 585
 - effect of [D-Tryp⁶]LHRH ethylamide + testosterone (dog), 585
- Testosterone + [D-Tryp⁶,des-Gly-NH₂¹⁰]LHRH ethylamide, effect on spermatogenesis (dog), 585
- Testosterone level,
 - effect of desogestrel, 73
 - effect of lynestrenol, 73
 - effect of [D-Tryp⁶]LHRH ethylamide (dog), 483, 585
 - effect of [D-Tryp⁶]LHRH ethylamide + testosterone (dog), 585
- Tetracycline, effect of intrauterine administration on genital tract morphology (monkey), 161
- Thrombin time,
 - effect of ethinylestradiol + levonorgestrel, 421
 - effect of levonorgestrel, 421
 - effect of mestranol + norethisterone, 421

CONTRACEPTION

- Thyroxine binding globulin level,
 effect of desogestrel, 73
 effect of lynestrenol, 73
- Time of sterilization, influence on prognosis, 339
- Time- and dose-dependent alterations of basal and LH-RH-stimulated LH release,
 treatment with various hormonal contraceptives (rat), 467
- Tissue-type plasminogen activator, regulatory effect of contraceptive
 steroids on release, 355
- α -Tocopherol acetate, effect on platelet lipid biosynthesis and aggregation
 with normal or vitamin E-deficient diet (rat), 279
- Tolbutamide metabolism, effect of gossypol (rat), 89
- Tolerance, progesterone pellets in lactating women, 311
- Transferrin level, effect of levonorgestrel, 407
- Triglycerides level,
 effect of ethinylloestradiol + desogestrel, 61
 effect of ethinylloestradiol + levonorgestrel, 61
 effect of levonorgestrel, 55, 413
- [D-Tryp⁶]LHRH ethylamide ([D-Tryp⁶,des-Gly-NH₂¹⁰]LHRH ethylamide
[D-Tryp⁶,des-Gly-NH₂¹⁰]LHRH ethylamide ([D-Tryp⁶]LHRH ethylamide),
 effect on spermatogenesis (dog), 585
 reversible inhibition of gonadal functions (dog), 483
- [D-Tryp⁶,des-Gly-NH₂¹⁰]LHRH ethylamide + testosterone, effect on
 spermatogenesis (dog), 585
- Tubal occlusion, effect of intrauterine quinacrine and tetracycline
 (monkey), 161
- Tubal sterilization,
 evaluation of luteal changes, 125
 laparoscopy and bipolar cauterization in a free-standing clinic, 545
- Tubal sterilization with Filshie Clip Mark IV, multicentre study, 339
- Urea + PGF₂ α , used with osmotic dilator or laminaria tent for
 midtrimester abortion, 215
- Ureaplasma urealyticum, effect of chemical intravaginal contraceptives
 and Betadine, 135
- Uterine contractility,
 effect of ORF 13811 (guinea pig), 39
 effect of PGF₂ α (guinea pig), 39
- Vaginal cytology,
 effect of desogestrel, 73
 effect of lynestrenol, 73
- Vessel walls of hind leg,
 effect of ethinylestradiol on fibrinolytic activity (rat), 169
 effect of d-norgestrel on fibrinolytic activity (rat), 169
- Vimule cervical cap, survey of use and efficacy, 115
- Vitamin A level, effect of ethinyl estradiol + levonorgestrel and
 multivitamin supplementation, 179
- Vitamin B-1 level, effect of ethinyl estradiol + levonorgestrel and
 multivitamin supplementation, 179
- Vitamin B-2 level, effect of ethinyl estradiol + levonorgestrel and
 multivitamin supplementation, 179
- Vitamin B-6 level, effect of ethinyl estradiol + levonorgestrel and
 multivitamin supplementation, 179
- Vitamin B-12 level, effect of ethinyl estradiol + levonorgestrel and
 multivitamin supplementation, 179
- Vitamin E, effect on platelet abnormalities induced by estrogen (rat), 279

CONTRACEPTION

- Vitamin E level, effect of ethinyl estradiol + levonorgestrel and multivitamin supplementation, 179
- Vitamin E level in platelets and plasma, effect of α -tocopherol and ethynylestradiol administration with normal or vitamin E-deficient diet (rat), 279
- Vitamin metabolism and effects of multivitamin supplementation, use of ethinyl estradiol + levonorgestrel, 179
- Weight of breast-fed children, effect of depot-medroxyprogesterone acetate in lactating women, 523
- Xanthurenic acid level, effect of ethinyl estradiol + levonorgestrel and multivitamin supplementation, 179